Navigation Links
HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates
Date:3/7/2012

An Atlanta research collaboration may be one step closer to finding a vaccine that will provide long-lasting protection against repeated exposures to human immunodeficiency virus (HIV). Scientists at Emory University and GeoVax Labs, Inc. developed a vaccine that has protected nonhuman primates against multiple exposures to simian immunodeficiency virus (SIV) given in three clusters over more than three years. SIV is the nonhuman primate version of HIV.

Harriet L. Robinson, PhD, chief scientific officer at GeoVax Labs, Inc., and former director of the division of microbiology and immunology at Yerkes National Primate Research Center, has been leading the research team with Rama Rao Amara, PhD, associate professor of microbiology and immunology, Yerkes National Primate Research Center and the Emory Vaccine Center.

The research was presented Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash.

The vaccine regimen included a DNA prime vaccine that co-expressed HIV proteins and granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a normal protein that promotes the initiation of immune responses and thus enhances the ability of the vaccine to elicit blocking antibodies for the SIV virus before it enters cells.

Vaccination consisted of two DNA inoculations at months 0 and 2 to prime the vaccine response and then two booster inoculations at months 4 and 6. The booster vaccine was MVA, an attenuated poxvirus expressing HIV proteins. Six months after the last vaccination, both vaccinated and unvaccinated animals were exposed to SIV through 12 weekly exposures, resulting in an 87 percent per exposure efficacy and 70 percent overall protection. Over the next two years uninfected animals were exposed multiple times in two more series, resulting in an 82 percent per exposure efficacy during the second series and an 84 percent per exposure efficacy during the third series.

"Repeated challenges in animals are used to mimic sexual transmission," says Robinson. "The hope is that the results in the nonhuman primate models will translate into vaccine-induced prevention in humans."

"It is impressive to note that protection could be observed against both neutralization sensitive and neutralization resistant viruses," says Amara.

Neutralization is the process by which some antibodies can block virus infection.

A first generation GeoVax DNA/MVA vaccine that does not co-express GM-CSF has shown excellent safety and reproducible vaccine responses in Phase 1 and 2a clinical trials in more than 400 uninfected people. These trials, supported and conducted by the National Institutes of Health HIV Vaccine Trials Network, have set the stage for the second-generation GM-CSF co-expressing vaccine to move from its initial Phase 1 safety testing slated to start in March of this year to a Phase 2b efficacy trial in participants who are at high risk of exposure to HIV. The vaccine is designed for a version of the virus prevalent in the Americas.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Headaches May Plague Many With HIV/AIDS
2. Children with HIV/AIDS falling through the cracks of treatment scale-up efforts
3. Despite Advances, HIV/AIDS Still Takes Heavy Emotional Toll
4. Advocates Push for Greater Awareness of HIV/AIDS
5. Preventing HIV/AIDS 1 SMS at a time
6. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
7. Boston Medical Center awarded $1M to expand HIV/AIDS patient care services
8. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
9. International AIDS Society urges world leaders at UN General Assembly High-Level Meeting on HIV/AIDS to integrate a fourth pillar -- HIV cure research -- into the global response to the epidemic
10. Key goals for building on 30 years of HIV/AIDS research
11. Preventing the spread of HIV/AIDS with humanized BLT mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Axiad IDS , a leading provider of trusted identities ... the company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this ... and proactively address potential cybersecurity threats before they happen. The annual list ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. ... on peri-implantitis in Las Vegas, NV, and the importance of treating ... disease consultation and leading care for peri-implantitis, with or without a referral. As ...
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... bleeding gums and chronic bad breath, can now receive laser gum disease treatments from ... R. Douglas Campbell and David Landau are raising awareness of the importance of receiving ...
(Date:5/22/2017)... ... May 22, 2017 , ... Patients who avoid necessary dental and endodontic ... in Mt. Kisco, NY from Advanced Endodontics of Westchester. This highly-trained team of endodontists ... One or more sedation methods may be recommended based on the severity of the ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
(Date:5/4/2017)... 2017  Fortuna Fix Inc. (" Fortuna "), a ... to eliminate the need for embryonic and fetal stem cells ... diseases. Fortuna announced today the launch ... Fehlings , MD, PhD; Father Kevin FitzGerald , S.J., ... Professor James Giordano , PhD. "We are ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
Breaking Medicine Technology: